{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:18:46Z","timestamp":1785417526131,"version":"3.56.0"},"reference-count":28,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006827","name":"Florida Department of Health","doi-asserted-by":"publisher","award":["7ZK02"],"award-info":[{"award-number":["7ZK02"]}],"id":[{"id":"10.13039\/100006827","id-type":"DOI","asserted-by":"publisher"}]},{"award":["7ZK02"],"award-info":[{"award-number":["7ZK02"]}],"id":[{"id":"https:\/\/ror.org\/03e1xkn26","id-type":"ROR","asserted-by":"publisher"}]},{"name":"Florida Cancer Innovation Fund"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Niclosamide is an U.S. Food and Drug Administration (FDA)-approved antihelminthic drug with a long-established safety profile and demonstrated in vitro antiviral activity against Zika virus. Its evaluation for systemic indications has been limited by its poor oral bioavailability. This Phase I study assessed whether oral administration of the approved niclosamide formulation could achieve plasma concentrations comparable to those with reported antiviral activity. Methods: This single-center, open-label, randomized, two-period crossover Phase I study evaluated the safety, tolerability, and pharmacokinetics of oral niclosamide in healthy adult volunteers. Twelve participants received niclosamide 2 g once daily for three consecutive days under fed or fasted conditions, followed by crossover after a 14-day washout period. Plasma niclosamide concentrations were quantified using a validated Liquid Chromatography-Mass Spectrometry (LC\u2013MS\/MS) assay, and pharmacokinetic parameters were derived via non-compartmental analysis. Safety assessments included adverse event monitoring, clinical laboratory testing, vital signs, electrocardiograms, and physical examinations. Results: Nine participants per protocol completed the study. Niclosamide was safe and well tolerated under both fed and fasted conditions, with only mild to moderate, transient adverse events and no serious or severe events. Systemic exposure was markedly higher following fed administration, with mean maximum observed plasma concentration (Cmax) and Area Under the Curve (AUC) values several-fold greater than those observed under fasted conditions. Under fed conditions, mean plasma niclosamide concentrations exceeded the reported in vitro Zika virus half-maximal inhibitory concentration (IC50) (0.22 \u00b5M) for approximately 9 h post-dose on both Day 1 and Day 3. Fasted administration did not consistently achieve this exposure threshold. No unexpected accumulation was observed with repeated once-daily dosing. Conclusions: Oral niclosamide administered at the approved daily dose of 2 g is safe and well tolerated in healthy volunteers. Administration with food substantially enhances systemic exposure and transiently achieves plasma concentrations associated with in vitro antiviral activity against Zika virus. These findings support further development of optimized niclosamide formulations to achieve sustained systemic exposure for antiviral therapeutic applications.<\/jats:p>","DOI":"10.3390\/jcm15145330","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T17:27:31Z","timestamp":1783531651000},"page":"5330","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["An Open Label, Cross-Over Phase 1 Study to Determine the Safety, Tolerability and Pharmacokinetics of Multiple Oral Doses of Niclosamide Under Fed and Fasted Conditions in Healthy Volunteers"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4804-6599","authenticated-orcid":false,"given":"Gary K.","family":"Ostrander","sequence":"first","affiliation":[{"name":"Department of Biomedical Sciences, College of Medicine, Florida State University, Tallahassee, FL 32306, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric H.","family":"Holmes","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, College of Medicine, Florida State University, Tallahassee, FL 32306, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"ref_1","first-page":"564","article-title":"\u00dcber ein neues Bandwurmmittel","volume":"8","author":"Lammler","year":"1958","journal-title":"Arzneimittelforschung"},{"key":"ref_2","first-page":"684","article-title":"Ein neues Molluskizid zur Bek\u00e4mpfung der Bilharziose","volume":"9","year":"1959","journal-title":"Arzneimittelforschung"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"550","DOI":"10.7326\/0003-4819-102-4-550","article-title":"Niclosamide therapy for tapeworm infections","volume":"102","author":"Pearson","year":"1985","journal-title":"Ann. Intern. Med."},{"key":"ref_4","unstructured":"Centers for Disease Control and Prevention (CDC) (1983). Licensure of Yomesan. MMWR Morb. Mortal. Wkly. Rep., 32, 75\u201376. Available online: https:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/00001103.htm."},{"key":"ref_5","first-page":"15","article-title":"Pharmacokinetics of anti-SARS-CoV agent niclosamide and its analogs in rats","volume":"14","author":"Chang","year":"2006","journal-title":"J. Food Drug Anal."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"127906","DOI":"10.1016\/j.bmcl.2021.127906","article-title":"Application of niclosamide and analogs as small molecule inhibitors of Zika virus and SARS-CoV-2 infection","volume":"40","author":"Shamim","year":"2021","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1158\/1535-7163.MCT-19-0689","article-title":"Preclinical testing of a novel niclosamide stearate prodrug therapeutic (NSPT) shows efficacy against osteosarcoma","volume":"19","author":"Reddy","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"117527","DOI":"10.1016\/j.ejmech.2025.117527","article-title":"Pharmacological advances and therapeutic applications of niclosamide in cancer and other diseases","volume":"290","author":"Laila","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Kaushal, J.B., Bhatia, R., Kanchan, R.K., Raut, P., Mallapragada, S., Ly, Q.P., Batra, S.K., and Rachagani, S. (2021). Repurposing niclosamide for targeting pancreatic cancer by inhibiting the Hh\/Gli non-canonical axis of GSK3\u03b2. Cancers, 13.","DOI":"10.3390\/cancers13133105"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"8870","DOI":"10.1182\/blood-2022-167429","article-title":"Niclosamide inhibits proliferation of leukemia cells and synergizes with chemotherapy","volume":"141","author":"Mark","year":"2022","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"776","DOI":"10.3892\/ijmm.2016.2689","article-title":"Niclosamide inhibits colon cancer progression through downregulation of the Notch pathway and upregulation of the tumor suppressor miR-200 family","volume":"38","author":"Suliman","year":"2016","journal-title":"Int. J. Mol. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1038\/bcj.2011.38","article-title":"Redeployment-based drug screening identifies the antihelminthic niclosamide as an anti-myeloma therapy that also reduces free light chain production","volume":"1","author":"Khanim","year":"2011","journal-title":"Blood Cancer J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.3892\/mmr.2017.6768","article-title":"Niclosamide attenuates inflammatory cytokines via the autophagy pathway leading to improved outcomes in renal ischemia\/reperfusion injury","volume":"16","author":"Zhang","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.2147\/IDR.S490998","article-title":"Drug repurposing: Research progress of niclosamide and its derivatives on antibacterial activity","volume":"17","author":"Liu","year":"2024","journal-title":"Infect. Drug Resist."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1093\/biolre\/ioaa010","article-title":"Niclosamide suppresses macrophage-induced inflammation in endometriosis","volume":"102","author":"Sekulovski","year":"2020","journal-title":"Biol. Reprod."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1007\/s12033-024-01296-2","article-title":"Exploring niclosamide as a multitarget drug against SARS-CoV-2: Molecular dynamics simulation studies on host and viral proteins","volume":"67","author":"Jagtap","year":"2025","journal-title":"Mol. Biotechnol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/nm.4184","article-title":"Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen","volume":"22","author":"Xu","year":"2016","journal-title":"Nat. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1021\/acsinfecdis.0c00052","article-title":"Broad spectrum antiviral agent niclosamide and its therapeutic potential","volume":"6","author":"Xu","year":"2020","journal-title":"ACS Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1021\/acsinfecdis.0c00217","article-title":"JMX0207, a niclosamide derivative with improved pharmacokinetics, suppresses zika virus infection both in vitro and in vivo","volume":"6","author":"Li","year":"2020","journal-title":"ACS Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1093\/jnci\/djr190","article-title":"Novel effect of antihelminthic niclosamide on S100A4-mediated metastatic progression in colon cancer","volume":"103","author":"Sack","year":"2011","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Arshad, U., Pertinez, H., Box, H., Tatham, L., Rajoli, R.K.R., Neary, M., Sharp, J., Valentijn, A., Hobson, J., and Unsworth, C. (2021). Optimisation and validation of a sensitive bioanalytical method for niclosamide. bioRxiv.","DOI":"10.1101\/2021.01.13.426426"},{"key":"ref_22","unstructured":"(2018). Medical Dictionary for Regulatory Activities (MedDRA\u00ae), International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Version 21.0."},{"key":"ref_23","unstructured":"World Health Organization (WHO) (2018). WHO Drug Dictionary (WHODD), Version March 2018 (B3), Uppsala Monitoring Centre."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/0035-9203(52)90042-4","article-title":"Zika virus. I. Isolations and serological specificity","volume":"46","author":"Dick","year":"1952","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMsr1604338","article-title":"Zika virus and birth defects\u2014Reviewing the evidence for causality","volume":"374","author":"Rasmussen","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1056\/NEJMoa1600651","article-title":"Zika Virus Associated with Microcephaly","volume":"374","author":"Mlakar","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S0140-6736(16)00562-6","article-title":"Guillain\u2013Barr\u00e9 syndrome outbreak associated with Zika virus infection in French Polynesia: A case\u2013control study","volume":"387","author":"Blake","year":"2016","journal-title":"Lancet"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Xu, J., Zhao, S., Teng, T., Abdalla, A.E., Zhu, W., Xie, L., Wang, Y., and Guo, X. (2020). Systematic comparison of two animal-to-human transmitted human coronaviruses: SARS-CoV-2 and SARS-CoV. Viruses, 12.","DOI":"10.3390\/v12020244"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/14\/5330\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T17:50:02Z","timestamp":1783533002000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/14\/5330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":28,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["jcm15145330"],"URL":"https:\/\/doi.org\/10.3390\/jcm15145330","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]}}}